British Journal of Cancer · 2021 · 42 citations · 22 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyDose Adjustment In OncologyMalignant NeoplasmsMelanoma PharmacotherapyMetastatic Disease TreatmentTargeted TherapyToxicity ManagementArgininosuccinate Synthetase DeficiencyDna Damage Repair PathwaysDna Damage Response PathwaysDna Repair PathwaysMetastatic Melanoma TreatmentPlatinum CompoundsPlatinum-based AgentsRecommended Phase 2 Dose
BACKGROUND: Arginine depletion interferes with pyrimidine metabolism and DNA damage-repair pathways, and pairing arginine deiminase pegylated with 20,000-molecular-weight polyethylene glycol (ADI-PEG20) with platinum enhances cytotoxicity in vitro and in vivo in arginine auxotrophs. METHODS: This single-centre, Phase 1 trial was conducted using a 3 + 3 dose escalation designed to assess safety, tolerability and determine the recommended Phase 2 dose (RP2D) of ADI-PEG20. RESULTS: We enrolled 99 patients with metastatic argininosuccinate synthetase 1 (ASS1) deficient malignancies. We observed no dose-limiting toxic effects or treatment-related mortality. Three percent of patients discontinued treatment because of toxicity. After treatment, 5% (5/99) of patients had partial responses, and 41% had stable disease. The median progression-free and overall survival durations were 3.62 and 8.06 months, respectively. Substantial arginine depletion and citrulline escalation persisted in most patients through weeks 24 and 8, respectively. Tumour responses were associated with anti-ADI-PEG20 antibody levels at weeks 8 and 16 (p = 0.031 and p = 0.0357, respectively). CONCLUSION: Concurrently administered ADI-PEG20 and cisplatin had an acceptable safety profile and had shown antitumour activity against metastatic ASS1-deficient solid tumours. Further evaluation of this treatment combination is warranted.
22
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Roger Geiger, Jan C. Rieckmann, Tobias Wolf et al. · Cell · 2016 · 1.7K citations · Full text
Ghassan K. Abou‐Alfa, Shukui Qin, Baek‐Yeol Ryoo et al. · Annals of Oncology · 2018 · 255 citations · Full text